Mission: The Cancer Research Institute (CRI) is the world's only nonprofit organization dedicated soley to advancing immunological research leading to the development of immune system-based treatments for cancer. CRI provides funding and coordination to support all levels of research in immunology and tumor immunology, from basic studies to clinical investigation of promising new cancer treatments.
Results: CRI has conducted more than 40 early stage clinical trials of unique cancer vaccines, and has made significant contributions to our knowledge of the human immune response to cancer immunotherapy. CRI researchers have also identified numerous cancer cell markers that are now being tested as targets for immunotherapy. CRI has empowered academic investigators around the world to conduct important clinical discovery, accelerating the translation of new knowledge into treatments for cancer patients.
Target demographics: Under the leadership of our Scientific Advisory Council, which includes 4 Nobel Laureates and 28 members of the National Academy of Sciences, CRI funds academic research in immunology and tumor immunology at universities and health research centers around the world.
Direct beneficiaries per year: Approximately 300 scientists and clinicians in 15 countries
Geographic areas served: National, International
Programs: Clinical Research: *Cancer Vaccine Collaborative, a joint program with the Ludwig Institute for Cancer Research, that supports a network of 19 academic clinical trial sites and immune monitoring laboratories around the world conducting early phase clinical trials of the most promising cancer immunotherapies; *the Cancer Immunotherapy Consortium, an association of more than 70 pharmaceutical & biotech companies and academic institutions engaged in late-stage product development that work together to shape the emerging field of immuno-oncology; *Cancer Vaccine Acceleration Fund, a unique venture philanthropy model designed to partner our clinical trials network with companies and their promising vaccine reagents.
Basic Research & Training: *Investigator Award program, providing 4 years of bridge support to newly established laboratories at universities; *Irvington Fellowship Program, provides 3 years of postdoctoral fellowship funding to talented scientists working under the mentorship of leading immunologists; *Predoctoral Pathways program, offering 4-year grants to universities to establish tumor immunology educational curriculum for graduate students.
Two years ago, we came up with a hypothesis relating to how immunotolerance is induced and maintained upon tumor development. With the help of financial support from the CRI, we have been able to throw more light on this pathway and our findings have the potential to translate into the development of novel immunotherapy approaches for the treatment of cancer. Thank you CRI